Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Kinases and Phosphatases
Special Issues
The PI3K Pathway in Human Disease from the Bench to...
share announcement

The PI3K Pathway in Human Disease from the Bench to the Clinic: There and Back Again

A special issue of Kinases and Phosphatases (ISSN 2813-3757).

Deadline for manuscript submissions: 30 July 2024 | Viewed by 761

Special Issue Editors

Prof. Dr. Sandra Marmiroli

E-Mail Website
Guest Editor
Department of Biomedical, Metabolic and Neuronal Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
Interests: cellular signaling; lipid-activated protein kinases; identification of isoform-specific substrates of the AKT protein kinase; modulation of glycolytic vs. oxidative cellular phenotypes by signaling pathways in acute leukemia models; definition of the phosphorylome of primary blast cells from leukemia patients, and its modulation by the PI3K pathway; kinase-inhibitor therapy in hematological malignancies
Special Issues, Collections and Topics in MDPI journals
Dr. Alessandro Poli

E-Mail Website
Guest Editor
1. National Institute of Molecular Genetics (INGM), 20122 Milan, Italy
2. The FIRC Institute of Molecular Oncology (IFOM), 20139 Milan, Italy
Interests: phosphoinositides; mechanobiology; immunology; cancer research; LINC-complex

Special Issue Information

Dear Colleagues,

Signaling of the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) represents a key intracellular pathway, regarded as a master regulator of cell processes and cellular functions (such as cell growth, proliferation, differentiation, motility, survival, and intracellular trafficking). However, it is also recognized as one of the most frequently altered pathways in human cancer, comprising the oncogene PIK3CA and the tumor suppressor gene PTEN, and dysfunction of the PI3K/AKT/mTOR pathway is implicated in several severe conditions, including cancer, cardiovascular disease, type 2 diabetes, autoimmune disorders, and neurological conditions. Despite its attractivity as a therapeutic target for the treatment of cancer in primis, as well as an accruing body of scientific knowledge and massive efforts devoted to the development of drug targeting PI3K signaling, only few molecules have translated into the clinic, and more are currently employed in clinical trial evaluation.

On these bases, this Special Issue aims to provide a platform for bench and clinic research on the different aspects and the numerous players of the PI3K pathway, with a special focus on resistance mechanisms in relation to PI3K/AKT/mTOR inhibition. We warmly welcome your submissions of original papers and reviews based on results from recent viewpoints.

This Special Issue is led by Dr. Sandra Marmiroli and Dr. Alessandro Poli, assisted by our Guest Editors' assistant editor Dr. Francesca Paganelli <> (Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, 40136 Bologna, Italy). 

Prof. Dr. Sandra Marmiroli
Dr. Alessandro Poli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Kinases and Phosphatases is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PI3K pathway
  • phosphatidylinositol-3-kinase
  • AKT
  • mTOR
  • inhibition
  • cancer
  • cardiovascular disease
  • type 2 diabetes
  • autoimmune disorders
  • human disease

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 2638 KiB  
Article
Short-Chain Fatty Acids Suppress mTOR Signaling in Colon Cancer Cells via Long Non-Coding RNA RMST
by Jiuhui Wang, Yande Guo, Xiangwei Fang, Yuanqin Zhang and Daotai Nie
Kinases Phosphatases 2024, 2(2), 136-150; https://doi.org/10.3390/kinasesphosphatases2020008 - 01 Apr 2024
Viewed by 478
Abstract
Short-chain fatty acids (SCFAs), derived from fermentation of dietary fibers and resistant starch by the microbiota in the colon, exert multiple effects on colonic functions, including tumor suppressing activities. Our previous studies found that SCFAs induced autophagy in colon cancer cells via downregulating [...] Read more.
Short-chain fatty acids (SCFAs), derived from fermentation of dietary fibers and resistant starch by the microbiota in the colon, exert multiple effects on colonic functions, including tumor suppressing activities. Our previous studies found that SCFAs induced autophagy in colon cancer cells via downregulating mTOR signaling, but the mechanism involved in mTOR suppression still needs to be defined. In this study, we identified rhabdomyosarcoma 2 associated transcript (RMST), a long non-coding RNA, as a key mediator for SCFAs to suppress mTOR activation in colon cancer cells. RMST could be significantly induced by SCFAs in a time- and dose-dependent manner. RMST, by itself, was sufficient to suppress mTOR signaling and augment autophagosome formation. Depletion of RMST, through siRNA or CRISPR knockdown, reduced the abilities of SCFAs to suppress mTOR activation or to induce autophagic responses. RMST increased the expression level of TSC2, a negative regulator of the mTOR signaling pathway. Our data delineate a novel RMST/TSC2 cellular pathway, enlisted by SCFAs, to modulate mTOR activities in colon cancer cells. Full article
(This article belongs to the Special Issue The PI3K Pathway in Human Disease from the Bench to the Clinic: There and Back Again)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop